Steve Sofen is an accomplished CMC leader who brings to Abata more than 20 years of experience in technical innovation, product development, and manufacturing alliance management and strategy.
Prior to Abata, Steve was an independent CMC consultant primarily focused on supporting biotech companies in the cell and gene therapy space. Previously, he was senior vice president of technical operations at Kaleido Biosciences, where he led the company’s technical operations function. Before that, Steve was vice president of technical operations at CRISPR Therapeutics, where he built the manufacturing organization and led CMC efforts, which resulted in filing an IND for a hemoglobinopathy cell therapy in less than 18 months and transferring an allogeneic, gene edited CAR-T program to external CDMOs. Earlier in his career, Steve held numerous CMC positions, including CMC team director at Biogen, where he was involved in cell and gene therapy collaborations with Sangamo, TIGET and AGTC, executive director of the Novartis-MIT Center for Continuous Manufacturing, and vice president of manufacturing operations project and product management at Genzyme.
Steve holds a Ph.D. in bioinorganic chemistry from the University of California.